Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Challenge Study with Monovalent Norovirus Vaccine

Trial Profile

A Phase 2 Challenge Study with Monovalent Norovirus Vaccine

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Norovirus Vaccine-Vaxart (Primary)
  • Indications Norovirus infections
  • Focus Therapeutic Use
  • Sponsors Vaxart
  • Most Recent Events

    • 09 Nov 2018 According to a Vaxart media release, due to a manufacturing issue, the norovirus GI.1 vaccine tablets failed release testing and the company now expect to initiate this phase 2 monovalent challenge study in the first half of 2019.Vaxart is working diligently to resolve the issue.
    • 02 Nov 2017 New trial record
    • 30 Oct 2017 According to an Aviragen Therapeutics media release, this study is expected to begin in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top